Physiomics PLC Physiomics awarded further contract by Merck (0522F)
05 Marzo 2020 - 1:00AM
UK Regulatory
TIDMPYC
RNS Number : 0522F
Physiomics PLC
05 March 2020
5 March 2020
Physiomics plc
("Physiomics") or (the "Company")
Physiomics awarded further contract by Merck
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models and its Virtual Tumour(TM) technology to
support the development of cancer treatment regimens and
personalised medicine solutions, is pleased to announce that it has
been awarded a further contract of undisclosed value by its
existing client Merck KGaA ("Merck").
This contract is an extension of one of the projects awarded and
announced on 20 December 2019. As stated at that time, Merck has
moved to a model where a number of projects will potentially be
signed over the course of the year rather than all of them being
agreed in advance as in previous years. This latest contract award
reinforces the new arrangement with Merck, and the Company hopes
that further contracts may be signed over the remaining course of
this calendar year.
This project extension is expected to be concluded over the next
six months.
Dr Jim Millen, CEO said : "We are delighted that the new
arrangement with our long-standing client, Merck, appears to be
working well, having already added our first additional project to
those announced in December 2019. We look forward to the
possibility of further new projects as the year progresses."
This announcement is released by Physiomics plc and contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in
accordance with the Company's obligations under Article 17 of
MAR.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0) 20 7409 3494
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC ) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 70 projects, involving over 30 targets and
60 drugs, and has worked with clients such as Merck KGaA, Merck
& Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 120 years collectively of working in
oncology and/or computational biology and over 120 publications in
peer reviewed journals that have attracted thousands of
citations.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
CNTEAPDLEEAEEFA
(END) Dow Jones Newswires
March 05, 2020 02:00 ET (07:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024